WuXi Biologics (Cayman) Inc., a company incorporated in the Cayman Islands, has announced the approval of a new grant of 64,117 restricted shares under its Restricted Share Award Scheme. The grant, approved by the Board on June 5, 2025, is subject to acceptance by the grantee. This decision aligns with the company's effort to allocate shares under the scheme, which currently has 187,681,267 restricted shares available for future grants. The Board, including independent non-executive directors, has deemed the grant as fair and reasonable, considering it beneficial for the interests of the company and its shareholders. The restricted shares are ordinary shares with a nominal value of US$1/120,000 each.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。